COSA 2017November 13 - 15, 2017

Breakfast Sessions

Monday 13th November

Building effective enterprise data solutions to support both practice and research. Meeting the needs of technologists and clinicians

Time: 7:00 - 8:15am
Date: Monday 13th November 2017
Description: More details coming soon!

Chair: TBA
Speaker: 
Dana Rollison

This breakfast session is supported by COSA 
COSA Logo BLUE RGB 72dpi

Tuesday 14th November

2nd line NSCLC - how new therapies are changing the Australian treatment landscape

Time: 07:00 - 08:45am 
Date: Tuesday 14th November 2017
Description: In 2017 the Australian treatment landscape in 2nd line non-small cell lung cancer (NSCLC) continues to rapidly change and evolve. New therapies in both non-mutation and mutation driven disease have recently become available allowing for greater choice in the treatment of this devastating disease.  The question now has become, how do these therapies differ and which of these differentiating factors are important to both clinicians and patients. Lastly, in this era of changing medicine with different mode of actions and corresponding side effect profiles, who else needs to be involved to ensure optimal care of 2nd line NSCLC? In this Roche-sponsored breakfast symposium Dr Adnan Nagrial will discuss “Treatment choices and managing patients with non-mutation 2nd line NSCLC” and Dr Steven Kao will discuss “Mutation driven 2nd line NSCLC – approach to targeted therapies”.  Prof Stephen Clarke will chair this session which aims to give Australian oncologists practical guidance on differentiating/choosing therapies and managing patients the rapidly evolving treatment landscape, particularly focusing on recent data and new therapies available to 2nd line NSCLC patients. 

Chair: Professor Stephen Clarke, Royal North Shore Hospital
Speakers:
Dr Adnan Nagrial, Crown Princess Mary Cancer Centre Westmead - "Managing patients with non-mutation 2nd line NSCLC" 
Dr Stephen Kao, Chris O'Brien Lifehouse - "Mutation driven 2nd line NSCLC - approach to targeted therapies" 

This breakfast session is supported by Roche

Roche blue logo

 

Return to work following a cancer diagnosis: Implications for cancer rehabilitation programs

Time: 7:00 - 8:45am
Date: Tuesday 14th November 2017
Description: This breakfast session provides an overview of issues related to employment, return to work and work ability among cancer survivors including aspects of modifiable risk factors, long term problems in affected workers and work satisfaction. Current theoretical models of the relationship between demographic, cancer and treatment-related as well as psychosocial factors on employment and work-related issues are presented and discussed. The workshop will include information about assessment tools and their applications. The workshop will introduce models of medical and occupational rehabilitation to assist cancer patients in coping with difficult situations at the workplace, problems in returning to work and job accommodations. Learning objectives: The attendee shall be able to understand the impact of cancer and treatment-related physical, psychosocial, and cognitive functioning on work ability and employment in cancer survivors, to become familiar with research and assessment tools measuring work-related aspects in cancer survivors and to become familiar current models of rehabilitation to assist patients in coping with work and employment-related problems.

Chair: TBA
Speaker: Dr Anja Mehnert

This breakfast session is supported by COSA 

COSA logo blue on white

Exploring the forgotten genome of cancer research

Time: 7:00 - 8:45am
Date: Tuesday 14th November 2017
Description: More detail coming soon!

Chair: Kahlil Lawless
Speaker: David Thomas, Garvan 

This breakfast session is supported by Illumina

Illumina

Wednesday 15th November

Moving Mountains in NSCLC - The New Era of IO for 1L Lung Cancer Treatment

Time: 7:00 - 8:45am
Date: Wednesday 15th November 2017
Description: Please join us for a scientific update on new treatment paradigms in 1L lung cancer and how these will impact clinical outcomes, with a specific focus on the role of immunotherapy.

More detail coming soon!

Chair: TBC
Speaker: TBC

This breakfast session is supported by MSD

MSD logo2

Becoming a pro with PRO

Time: 7:00 - 8:45am
Date: Wednesday 15th November 2017
Description: There is growing evidence that incorporating patient reported outcomes (PROs) into the care of patients with cancer is beneficial to patient care and health system planning. However, implementing PROs into routine practice is a complex undertaking that requires appropriate planning and support. In this session we will briefly review some of the history and evidence for use of PROs in oncology and spend the majority of our time discussing implementation issues drawing on existing experiences across healthcare systems and discuss approaches for successful implementation using a case-based approach.

Chair: Afaf Girgis

Speaker: Dr. Monika Krzyzanowska

This breakfast session is supported by COSA 
COSA Logo BLUE RGB 72dpi Copy

 

Scalp Cooling - Meeting the Growing Demand

Time: 7:00 - 8:45am
Date: Wednesday 15th November 2017

Chair: Dr Michelle White, Oncologist, Monash Health and Cabrini

Speaker: TBA

This breakfast session is supported by Regional Healthcare Group

logo p